Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Status Recruiting

Clinical Trial Summary

This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.

Clinical Trial Description

The goal of the Phase 0 component is to determine if MMF achieves active concentrations in brain tumors. Eight participants in Phase 0 will receive MMF for one week before undergoing an already planned biopsy or re-resection (surgical removal) of glioblastoma or gliosarcoma (GBM/GS). A small portion of the tumor, removed as part of clinical care, will be used for testing in this study. Sixty additional participants will be enrolled in the Phase 1 component of the trial (30 with recurrent GBM/GS and 30 with newly diagnosed GBM/GS). The goal of the Phase 1 component is to find the dose of MMF that works best without causing severe side effects (the maximum tolerated dose) when combined with radiation in recurrent GBM/GS and with radiation and chemotherapy in newly diagnosed GBM/GS. Participants in Phase 0 who meet the eligibility criteria for the Phase 1 component may participate in both phases. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04477200
Study type	Interventional
Source	University of Michigan Rogel Cancer Center
Contact
Status	Recruiting
Phase	Phase 1
Start date	August 5, 2020
Completion date	October 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05577091` - Tris-CAR-T Cell Therapy for Recurrent Glioblastoma	Phase 1
Recruiting	`NCT05284643` - Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma	N/A
Recruiting	`NCT05039281` - Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma	Phase 1/Phase 2
Recruiting	`NCT04988750` - Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients	N/A
Recruiting	`NCT06058988` - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer	Phase 2
Completed	`NCT00503204` - Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour	Phase 1
Completed	`NCT03216499` - HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma	Phase 2
Not yet recruiting	`NCT04717999` - Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma	N/A
Not yet recruiting	`NCT05540275` - Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma	Phase 2
Recruiting	`NCT04528680` - Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma	Phase 1/Phase 2
Completed	`NCT04044937` - Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms	Phase 2
Recruiting	`NCT04888611` - Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma	Phase 2
Completed	`NCT00390299` - Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme	Phase 1
Recruiting	`NCT05463848` - Surgical Pembro +/- Olaparib w TMZ for rGBM	Phase 2
Active, not recruiting	`NCT04479241` - LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma	Phase 2
Active, not recruiting	`NCT00777153` - Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma	Phase 3
Withdrawn	`NCT05017610` - Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma	Early Phase 1
Recruiting	`NCT04323046` - Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults	Phase 1
Active, not recruiting	`NCT05324501` - A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma	Phase 1
Withdrawn	`NCT05666349` - Reirradiation and Niraparib in Patients With Recurrent Glioblastoma	Phase 1